We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BG Medicine Inc (CE) | USOTC:BGMD | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 00:00:00 |
As filed with the Securities and Exchange Commission on March 29, 2016
Registration No. 333-181700
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
POST-EFFECTIVE
AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
BG MEDICINE, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 04-3506204 | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
303 Wyman Street, Suite 300, Waltham, Massachusetts | 02451 | |
(Address of Principal Executive Offices) | (Zip Code) |
BG MEDICINE, INC. 2010 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN
BG MEDICINE, INC. 2010 EMPLOYEE STOCK PURCHASE PLAN
(Full Titles of the Plans)
Paul R. Sohmer, M.D.
President and Chief Executive Officer
BG Medicine, Inc.
303 Wyman Street, Suite 300
Waltham, Massachusetts 02451
(781) 890-1199
(Name, Address and Telephone Number, Including Area Code, of Agent for Service)
Copies to:
William T. Whelan, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
(617) 542-6000
Facsimile: (617) 542-2241
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ¨ | Accelerated filer | ¨ | |||
Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller reporting company | x |
DEREGISTRATION OF UNSOLD SECURITIES
The Registrant is filing this Post-Effective Amendment No. 1 (Post-Effective Amendment) to the Registration Statement on Form S-8 (Registration No. 333-181700), filed on May 25, 2012, which registered an aggregate of 494,990 shares of common stock issuable to participants in the Registrants 2010 Employee, Director and Consultant Stock Plan and 2010 Employee Stock Purchase Plan. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statement which remain unsold at the termination of the offering, the Registrant hereby amends the Registration Statement to deregister any remaining securities registered and unsold under the Registration Statement. The securities are being removed from registration because the securities are no longer being offered or sold pursuant to the Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to its Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, State of Massachusetts on March 29, 2016.
BG MEDICINE, INC. | ||
By: |
/s/ Paul R. Sohmer, M.D. |
|
Paul R. Sohmer, M.D. | ||
President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date |
||
/s/ Paul R. Sohmer, M.D. Paul R. Sohmer, M.D. |
President, Chief Executive Officer and Director (principal executive officer) | March 29, 2016 | ||
/s/ Stephen P. Hall Stephen P. Hall |
Executive Vice President, Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer) | March 29, 2016 | ||
/s/ Jeffrey R. Luber Jeffrey R. Luber |
Director | March 29, 2016 | ||
/s/ James F. OConnor James F. OConnor |
Director | March 29, 2016 | ||
/s/ Stelios Papadopoulos, Ph.D. Stelios Papadopoulos, Ph.D. |
Director, Vice Chairman of the Board | March 29, 2016 | ||
/s/ Harry W. Wilcox Harry W. Wilcox |
Director, Chairman of the Board | March 29, 2016 |
1 Year BG Medicine (CE) Chart |
1 Month BG Medicine (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions